Merck's Q2 2025 earnings call reveals revenue of $15.8B, strategic growth plans with a $3B reinvestment initiative, and confidence in driving ...

The restructuring includes the elimination of certain roles and a reduction in the company’s global real estate footprint.

Merck & Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed ...

Merck said Tuesday it will cut $3 billion in costs by 2027 and fully reinvest the savings to support new drug launches and pipeline development, according to CNBC. The restructuring comes as Merck ...

Wall Street traders sent stocks lower in the run-up to the Federal Reserve decision, with concerns about high valuations ...

Merck plans to cut jobs as part of a $3 billion cost-reduction strategy by 2027, while also lowering its 2025 revenue ...

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...

Along with its financial results for the second quarter of 2025, Merck revealed a restructuring plan to save $3 billion by ...

MSD has joined fellow big pharmas in looking to redirect cash, as the drugmaker revealed plans to save $3bn annually by the end of 2027.

CEO Rob Davis referred to the cost reduction program as a “reallocation” rather than a cut, with the savings to be reinvested ...

Merck is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the ...

Procter & Gamble Co. said it’s open to an acquisition in the consumer health care category, citing its successful purchase of ...